A golden age of asthma research. Issue 6 (24th December 2020)

• Record Type: Journal Article
• Authors: O'Byrne, Paul M.; Pavord, Ian D.
• Is Part Of: European respiratory journal. Volume 56:Issue 6(2020)
• Publication Date: 2020-12-24
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.03820-2020
• Languages: English
• ISSNs: 0903-1936

Abstract

More than a decade ago, there was a widely held opinion among respiratory clinicians and researchers that asthma was, for the most part, solved and not worth investing intellectual or financial capital into research. There was certainly a small proportion of the asthma population (<10%) with severe refractory asthma, who merited attention [1]; but the vast majority of asthmatic patients were well served with the available treatment armamentarium of rapid onset bronchodilators (mainly short-acting inhaled β2 -agonists (SABAs)), inhaled corticosteroids (ICS), or ICS and long-acting inhaled β2 -agonist (LABA) combinations delivered from a single inhaler. There has been an extraordinary increase in the understanding of asthma pathogenesis and treatment over the past decade. The ERJ is launching a series of reviews to highlight these advances in asthma and identify areas that still require investigation. https://bit.ly/2HrPfpO